Literature DB >> 17499764

Adiponectin protects against the development of systolic dysfunction following myocardial infarction.

Rei Shibata1, Yasuhiro Izumiya, Kaori Sato, Kyriakos Papanicolaou, Shinji Kihara, Wilson S Colucci, Flora Sam, Noriyuki Ouchi, Kenneth Walsh.   

Abstract

There is an association between obesity and heart failure associated with LV dysfunction. Adiponectin is an adipocyte-derived hormone that is downregulated in obesity. Here, we examined the role of adiponectin in cardiac remodeling after myocardial infarction with loss- and gain-of-function genetic manipulations in an experimental model. Myocardial infarction was created in adiponectin-deficient (APN-KO) and wild-type (WT) mice by the permanent ligation of the left anterior descending (LAD) artery. For some experiments, adenoviral vectors expressing adiponectin or beta-galactosidase were delivered systemically. Cardiac structure and function were assessed by echocardiographic and Millar catheter measurements. Myocardial capillary density was assessed by staining with anti-CD31 antibody. Myocyte apoptotic activity was determined by TUNEL-staining. Myocardial interstitial fibrosis was evaluated by Masson's trichrome staining. APN-KO mice showed exacerbated left ventricular (LV) dilation, myocyte hypertrophy and contractile dysfunction compared with WT mice at 4 weeks after LAD ligation. Impaired LV function in APN-KO mice was coupled to myocyte hypertrophy, increased apoptotic activity and interstitial fibrosis in the remote zone, and reduced capillary density in the infarct border zone. No difference in infarct size was observed between WT and APN-KO mice. Administration of adenovirus-mediated adiponectin in WT mice resulted in decreased LV dilatation and improved LV function that was associated with increased capillary density in the infarct border zone and decreased myocyte hypertrophy, diminished myocardial apoptosis and decreased interstitial fibrosis in the remote zone. These data suggest that adiponectin protects against the development of systolic dysfunction after myocardial infarction through its abilities to suppress cardiac hypertrophy and interstitial fibrosis, and protect against myocyte and capillary loss.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17499764      PMCID: PMC1987393          DOI: 10.1016/j.yjmcc.2007.03.808

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  44 in total

1.  Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure.

Authors:  Caroline Kistorp; Jens Faber; Søren Galatius; Finn Gustafsson; Jan Frystyk; Allan Flyvbjerg; Per Hildebrandt
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

2.  Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms.

Authors:  Rei Shibata; Kaori Sato; David R Pimentel; Yukihiro Takemura; Shinji Kihara; Koji Ohashi; Tohru Funahashi; Noriyuki Ouchi; Kenneth Walsh
Journal:  Nat Med       Date:  2005-09-11       Impact factor: 53.440

3.  Adiponectin and risk of congestive heart failure.

Authors:  Erik Ingelsson; Ulf Risérus; Christian Berne; Jan Frystyk; Allan Flyvbjerg; Tomas Axelsson; Per Lundmark; Björn Zethelius
Journal:  JAMA       Date:  2006-04-19       Impact factor: 56.272

4.  Adiponectin replacement therapy attenuates myocardial damage in leptin-deficient mice with viral myocarditis.

Authors:  T Takahashi; S Saegusa; H Sumino; T Nakahashi; K Iwai; S Morimoto; T Kanda
Journal:  J Int Med Res       Date:  2005 Mar-Apr       Impact factor: 1.671

5.  Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload.

Authors:  Yasuhiro Izumiya; Ichiro Shiojima; Kaori Sato; Douglas B Sawyer; Wilson S Colucci; Kenneth Walsh
Journal:  Hypertension       Date:  2006-03-27       Impact factor: 10.190

6.  Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism.

Authors:  Yulin Liao; Seiji Takashima; Norikazu Maeda; Noriyuki Ouchi; Kazuo Komamura; Iichiro Shimomura; Masatsugu Hori; Yuji Matsuzawa; Tohru Funahashi; Masafumi Kitakaze
Journal:  Cardiovasc Res       Date:  2005-09-01       Impact factor: 10.787

7.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart.

Authors:  Y Fujio; T Nguyen; D Wencker; R N Kitsis; K Walsh
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

8.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.

Authors:  N Ouchi; S Kihara; Y Arita; K Maeda; H Kuriyama; Y Okamoto; K Hotta; M Nishida; M Takahashi; T Nakamura; S Yamashita; T Funahashi; Y Matsuzawa
Journal:  Circulation       Date:  1999 Dec 21-28       Impact factor: 29.690

9.  Adiponectin-mediated modulation of hypertrophic signals in the heart.

Authors:  Rei Shibata; Noriyuki Ouchi; Masahiro Ito; Shinji Kihara; Ichiro Shiojima; David R Pimentel; Masahiro Kumada; Kaori Sato; Stephan Schiekofer; Koji Ohashi; Tohru Funahashi; Wilson S Colucci; Kenneth Walsh
Journal:  Nat Med       Date:  2004-11-21       Impact factor: 53.440

10.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

Authors:  Ichiro Shiojima; Kaori Sato; Yasuhiro Izumiya; Stephan Schiekofer; Masahiro Ito; Ronglih Liao; Wilson S Colucci; Kenneth Walsh
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

View more
  74 in total

1.  Gender differences in adiponectin modulation of cardiac remodeling in mice deficient in endothelial nitric oxide synthase.

Authors:  Jorge L Durand; Andrea R Nawrocki; Philipp E Scherer; Linda A Jelicks
Journal:  J Cell Biochem       Date:  2012-10       Impact factor: 4.429

2.  Adiponectin reduces C-reactive protein expression and downregulates STAT3 phosphorylation induced by IL-6 in HepG2 cells.

Authors:  Haiyun Sun; Yingnan Zhang; Ping Gao; Qiang Li; Yuqian Sun; Jinchao Zhang; Changqing Xu
Journal:  Mol Cell Biochem       Date:  2010-10-27       Impact factor: 3.396

3.  Cardioprotective effect of intermittent fasting is associated with an elevation of adiponectin levels in rats.

Authors:  Ruiqian Wan; Ismayil Ahmet; Martin Brown; Aiwu Cheng; Naomi Kamimura; Mark Talan; Mark P Mattson
Journal:  J Nutr Biochem       Date:  2009-05-07       Impact factor: 6.048

4.  Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.

Authors:  Brian A Bergmark; Christopher P Cannon; William B White; Petr Jarolim; Yuyin Liu; Marc P Bonaca; Faiez Zannad; David A Morrow
Journal:  Diabetes Obes Metab       Date:  2017-03-17       Impact factor: 6.577

5.  T-cadherin is critical for adiponectin-mediated cardioprotection in mice.

Authors:  Martin S Denzel; Maria-Cecilia Scimia; Philine M Zumstein; Kenneth Walsh; Pilar Ruiz-Lozano; Barbara Ranscht
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

6.  Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response.

Authors:  Masayuki Shimano; Noriyuki Ouchi; Rei Shibata; Koji Ohashi; David R Pimentel; Toyoaki Murohara; Kenneth Walsh
Journal:  J Mol Cell Cardiol       Date:  2010-03-04       Impact factor: 5.000

7.  AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings.

Authors:  Yanqing Zhang; Jianli Zhao; Rui Li; Wayne Bond Lau; Yue-Xing Yuan; Bin Liang; Rong Li; Er-He Gao; Walter J Koch; Xin-Liang Ma; Ya-Jing Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-06-02       Impact factor: 4.310

Review 8.  Cardiomyocyte apoptosis in animal models of obesity.

Authors:  Premal S Trivedi; Lili A Barouch
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

9.  Adiponectin downregulation is associated with volume overload-induced myocyte dysfunction in rats.

Authors:  Li-li Wang; Dori Miller; Desiree Wanders; Gayani Nanayakkara; Rajesh Amin; Robert Judd; Edward E Morrison; Ju-ming Zhong
Journal:  Acta Pharmacol Sin       Date:  2015-11-30       Impact factor: 6.150

10.  Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice.

Authors:  Adrienn Kis; Colin Murdoch; Min Zhang; Anjana Siva; Sergio Rodriguez-Cuenca; Stefania Carobbio; Agnes Lukasik; Margaret Blount; Steve O'Rahilly; Sarah L Gray; Ajay M Shah; Antonio Vidal-Puig
Journal:  Eur J Heart Fail       Date:  2009-04-24       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.